Efficacy and Safety in the KEYNOTE-966 Study of Pembrolizumab (Pembro) Plus Gemcitabine and Cisplatin (gem/cis) for Advanced Biliary Tract Cancer (BTC): Impact of Hepatitis B Virus (HBV) Infection

Yau, T.Chan, S. L.Kelley, R. K.Finn, R. S.Yoo, C.Furuse, J.Qin, S.2025-08-252025-08-2520240923-75341569-8041https://doi.org/10.1016/j.annonc.2024.10.169https://hdl.handle.net/20.500.14365/6348eninfo:eu-repo/semantics/closedAccessEfficacy and Safety in the KEYNOTE-966 Study of Pembrolizumab (Pembro) Plus Gemcitabine and Cisplatin (gem/cis) for Advanced Biliary Tract Cancer (BTC): Impact of Hepatitis B Virus (HBV) InfectionConference Object10.1016/j.annonc.2024.10.169